Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Imatinib-resistant GIST, drawn from the whole corpus: 8 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Polyclonal resistance means no single inhibitor covers every metastasis.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Each later line adds months, not years, and toxicity accumulates.
Whether circulating tumour DNA-guided sequencing improves survival is unproven until INSIGHT reports.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
PFS HR 0.
A milestone in how this cancer is treated.
Regorafenib lengthened progression-free survival compared with placebo in GIST after imatinib and sunitinib; approved in February 2013.
A milestone in how this cancer is treated.